Precision AI that finds the patients driving clinical trial success.
NetraAI is the only clinical-trial AI platform reviewed in a closed-door FDA Critical Path Innovation Meeting. Peer-reviewed in the Nature portfolio. Embedded in CRO-led Phase 2 and Phase 3 trials worldwide.
Pharma collects massive trial data — and misses the signals that matter.
Sources: TransCelerate BioPharma & Tufts CSDD (2025); Chart Pack Biopharmaceuticals in Perspective (2020); Fierce Biotech (2025).
Explainable AI that finds who is driving the signal.
From sponsor data to protocol-ready criteria for the next trial — in four steps, with every subgroup defined by 2–4 interpretable variables.
- 01Sponsor dataPhase 1–3 trial datasets
- 02NetraAI analysisProprietary AI identifies hidden subpopulations
- 03Explainable subgroups2–4 key variables define each subgroup
- 04Trial strategyProtocol/SAP-ready criteria for next-phase design
Why this cannot be easily replicated.
FDA Critical Path Innovation Meeting
NetraAI is the only clinical-trial AI platform to have undergone a closed-door FDA CPIM. No traditional AI, ML, Bayesian, or standard statistical approach has achieved this level of regulatory engagement.
Purpose-built for trials
Designed from the ground up for small, high-dimensional datasets. Produces explicit variable bundles and patient membership every run — Model-Derived Subgroups defined by 2–4 interpretable variables.
Regulatory Defensibility Index
Published five-component RDI framework designed for the FDA's emerging AI-native review environment (Elsa/HALO). Stress-tests subgroup claims across stability, fragility, placebo structure, mechanistic coherence, and evidence calibration.